Zolinza (Vorinostat) - Summary

ZOLINZA SUMMARY

ZOLINZA™ (vorinostat) Capsules

ZOLINZA contains vorinostat, an antineoplastic agent, which is described chemically as N- hydroxy- N'- phenyloctanediamide.

ZOLINZA¹ is indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies.

ZOLINZA is a histone deacetylase (HDAC) inhibitor indicated for:

• Treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies. (1)

ZOLINZA NEWS HIGHLIGHTS

Media Articles Related to Zolinza (Vorinostat)

Tumor Surroundings Influence Survival in Diffuse Large-B-Cell Lymphoma
Source: MedPage Today Hematology/Oncology [2008.11.26]

Genes May Predict Lymphoma Treatment Outcome (HealthDay)
Source: Y! Health Lymphoma News [2008.11.26]

FDA Grants Pralatrexate Orphan Drug Designation For The Treatment Of Patients With Diffuse Large B-Cell Lymphoma
Source: Blood / Hematology News From Medical News Today [2008.11.25]

Lymphoma Association Launches New Short Film
Source: Lymphoma / Leukemia News From Medical News Today [2008.11.20]

Researchers Aim To Over-stress Already Taxed Mantle Cell Lymphoma Cells
Source: Lymphoma / Leukemia News From Medical News Today [2008.11.11]

more >>

Published Studies Related to Zolinza (Vorinostat)

FDG-PET/CT for the Evaluation of Response to Therapy of Cutaneous T-cell Lymphoma to Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in a Phase II Trial. [2008.11]

Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. [2008.10]

Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. [2008.09.01]

FDG-PET/CT for the Evaluation of Response to Therapy of Cutaneous T-cell Lymphoma to Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in a Phase II Trial. [2008.07.30]

Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. [2008.05.15]

more >>

Clinical Trials Related to Zolinza (Vorinostat)

A Phase I/II Clinical Trial of an Experimental Cancer Drug in Combination With an FDA Approved Cancer Drug for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer [Terminated]

Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors [Active, not recruiting]

Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies. [Recruiting]

A Crossover Study to Assess the Effects of Vorinostat (MK0683, SAHA) in Patients With Advanced Cancer [Recruiting]

Proteasome Inhibitor NPI-0052 and Vorinostat in Patients With Non-Small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma [Recruiting]

more >>